AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29397139 — intervention group
Group type: EXPERIMENTAL
Intervention: No preoperative APT
Number of subjects: 432
Study 29397139 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding events (MBE)
Number of subjects: 432
Study 29397139 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent myocardial infarction
Number of subjects: 432
Study 29397139 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 432
Study 29397139 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes
Number of subjects: 432
Study 29397225 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination with polygeline-free inactivated TBE vaccine (TBEvac)
Number of subjects: 191
Study 29397305 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation carriers
Number of subjects: 0
Study 29397305 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers
Number of subjects: 0
Study 29397334 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-150 keV noise-optimized virtual monoenergetic images
Number of subjects: 51
Study 29397334 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 keV noise-optimized virtual monoenergetic images
Number of subjects: 51
Study 29397334 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-70 keV noise-optimized virtual monoenergetic images and 70 keV virtual monoenergetic images
Number of subjects: 51
Study 29397334 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 keV noise-optimized virtual monoenergetic images
Number of subjects: 51
Study 29398518 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperemesis gravidarum (HG)
Number of subjects: 79
Study 29398518 — intervention group
Group type: COMPARATOR
Intervention: Control (no Hyperemesis gravidarum)
Number of subjects: 79
Study 29398546 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists
Number of subjects: 4111
Study 29398546 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 4111
Study 29398546 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 4111
Study 29398546 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4111
Study 29398594 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix for 8 weeks
Number of subjects: 50
Study 29398640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab intervention
Number of subjects: 572
Study 29398998 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily
Number of subjects: 22
Study 29398998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 29399054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets (CT) 3.5 mg/kg
Number of subjects: 0
Study 29399054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29399258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol Disoxate (LEO 43204), treatment duration not specified
Number of subjects: 0
Study 29399263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol Disoxate (LEO 43204)
Number of subjects: 0
Study 29399976 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week very-low-calorie diet (500 kcal/d) followed by a 4-week weight-stable diet (WS)
Number of subjects: 31
Study 29399976 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled 9-month follow-up
Number of subjects: 31
Study 29400693 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucus plugs in subjects with asthma
Number of subjects: 146
Study 29400693 — intervention group
Group type: COMPARATOR
Intervention: Mucus plugs in controls
Number of subjects: 146
Study 29400693 — intervention group
Group type: EXPERIMENTAL
Intervention: High mucus score (plugs in ≥ 4 segments) in subjects with asthma
Number of subjects: 146
Study 29400693 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil peroxidase (EPO) activity
Number of subjects: 146
Study 29401002 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib 400 mg once daily
Number of subjects: 134
Study 29401002 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib 150 mg twice daily
Number of subjects: 134
Study 29401002 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib (various doses)
Number of subjects: 134
Study 29401079 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol pharmacokinetic (PK) pharmacodynamic (PD) model
Number of subjects: 47
Study 29401079 — intervention group
Group type: EXPERIMENTAL
Intervention: Current model
Number of subjects: 47
Study 29401079 — intervention group
Group type: COMPARATOR
Intervention: PK model developed by Eleveld et al
Number of subjects: 47
Study 29401080 — intervention group
Group type: COMPARATOR
Intervention: Continuous oxytocin pretreatment (10(-5) M for 2 hours)
Number of subjects: 18
Study 29401080 — intervention group
Group type: COMPARATOR
Intervention: Intermittent oxytocin pretreatment (alternating 10(-5) M and physiological salt solution every 15 minutes for 2 hours)
Number of subjects: 18
Study 29401080 — intervention group
Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 18
Study 29402064 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose intravenous alteplase (0.9 mg/kg)
Number of subjects: 351
Study 29402064 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous alteplase (0.6 mg/kg)
Number of subjects: 351
Study 29402064 — intervention group
Group type: COMPARATOR
Intervention: Both doses of intravenous alteplase
Number of subjects: 351
Study 29402187 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced inpatient rounds, appointment reminders, and patient education
Number of subjects: 240
Study 29402187 — intervention group
Group type: COMPARATOR
Intervention: Preintervention period (control)
Number of subjects: 240
Study 29402187 — intervention group
Group type: COMPARATOR
Intervention: New diagnosis of HIV infection (control)
Number of subjects: 240
Study 29402243 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs), specifically gefitinib
Number of subjects: 334
Study 29402243 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 334
Study 29402243 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 334
Study 29402246 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal social networks (size=5.6, SD=2.6), kin-centered (proportion kin=0.71, SD=0.28), and dense networks.
Number of subjects: 700
Study 29402246 — intervention group
Group type: EXPERIMENTAL
Intervention: Affiliation with religious and spiritual organizations.
Number of subjects: 700
Study 29402246 — intervention group
Group type: EXPERIMENTAL
Intervention: Networks with higher density and more kin.
Number of subjects: 700
Study 29402313 — intervention group
Group type: EXPERIMENTAL
Intervention: Care supported by a dedicated 'community-acquired pneumonia service' (multidisciplinary team deploying algorithm-based implementation of a bundle of four evidence-based interventions)
Number of subjects: 8
Study 29402313 — intervention group
Group type: EXPERIMENTAL
Intervention: Care supported by a dedicated 'community-acquired pneumonia service'
Number of subjects: 8
Study 29402313 — intervention group
Group type: COMPARATOR
Intervention: Usual medical, nursing and allied health care delivered according to existing organisational practice
Number of subjects: 8
Study 29402319 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and treatment programme combined with flash glucose monitoring device
Number of subjects: 0
Study 29402319 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 29402444 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal alar sensor
Number of subjects: 43
Study 29402444 — intervention group
Group type: COMPARATOR
Intervention: Forehead sensor
Number of subjects: 43
Study 29402632 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight video-EEG (average 9.65h)
Number of subjects: 16
Study 29402632 — intervention group
Group type: COMPARATOR
Intervention: Routine EEG (approximately 25min)
Number of subjects: 16
Study 29402632 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up EEG
Number of subjects: 16
Study 29402632 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall EEG findings
Number of subjects: 16
Study 29402632 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical observation
Number of subjects: 16
Study 29402761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit One worn daily throughout the 12-week intervention
Number of subjects: 42
Study 29402761 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported frequency of looking at activity data on the Fitbit tracker and app or website at week 12
Number of subjects: 42
Study 29403411 — intervention group
Group type: EXPERIMENTAL
Intervention: Tools of the Mind preschool curriculum
Number of subjects: 260
Study 29403411 — intervention group
Group type: COMPARATOR
Intervention: YMCA PTL (Playing to Learn)
Number of subjects: 260
Study 29403482 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (RV5)
Number of subjects: 2
Study 29403531 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-monocyte apheresis
Number of subjects: 33
Study 29403650 — intervention group
Group type: EXPERIMENTAL
Intervention: RESHAPE intervention
Number of subjects: 0
Study 29403650 — intervention group
Group type: COMPARATOR
Intervention: Training as usual (TAU)
Number of subjects: 0
Study 29404331 — intervention group
Group type: EXPERIMENTAL
Intervention: 17.5 g/day cooked navy bean powder
Number of subjects: 38
Study 29404331 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g/day heat-stabilized rice bran
Number of subjects: 38
Study 29404331 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g/day navy beans and 8 g/day rice bran
Number of subjects: 38
Study 29404331 — intervention group
Group type: COMPARATOR
Intervention: no navy bean or rice bran (control)
Number of subjects: 38
Study 29404492 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) with concomitant proton pump inhibitor (PPI) use
Number of subjects: 1322
Study 29404492 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR) without concomitant proton pump inhibitor (PPI) use
Number of subjects: 1322
Study 29404572 — intervention group
Group type: EXPERIMENTAL
Intervention: Rideshare-based transportation services (complimentary ride-sharing)
Number of subjects: 786
Study 29404572 — intervention group
Group type: COMPARATOR
Intervention: Usual care (automated appointment phone call reminders)
Number of subjects: 786
Study 29404713 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 155 U every 12 weeks for 9 treatment cycles (108 weeks)
Number of subjects: 716
Study 29404723 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation (NIV)
Number of subjects: 130
Study 29404723 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical cough assistance
Number of subjects: 130
Study 29404723 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV and mechanical cough assistance
Number of subjects: 130
Study 29404723 — intervention group
Group type: EXPERIMENTAL
Intervention: Reintubation
Number of subjects: 130
Study 29404723 — intervention group
Group type: COMPARATOR
Intervention: Chronic respiratory disease
Number of subjects: 130
Study 29404723 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal MV duration
Number of subjects: 130
Study 29404723 — intervention group
Group type: COMPARATOR
Intervention: Medical Research Council (MRC) score
Number of subjects: 130
Study 29404723 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced vital capacity (FVC)
Number of subjects: 130
Study 29404723 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak cough expiratory flow (PCEF)
Number of subjects: 130
Study 29404723 — intervention group
Group type: COMPARATOR
Intervention: ROC curves for pre-extubation PCEF and FVC
Number of subjects: 130
Study 29405350 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurogenic OH (378 patients)
Number of subjects: 402
Study 29405350 — intervention group
Group type: COMPARATOR
Intervention: Nonneurogenic OH (24 patients)
Number of subjects: 402
Study 29405350 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔHR/ΔSBP ratio
Number of subjects: 402
Study 29405350 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurogenic OH (multiple system atrophy subgroup)
Number of subjects: 402
Study 29405538 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic patient-reported outcome (ePRO) collection system
Number of subjects: 0
Study 29405626 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan 0.75 mg once daily for 6 weeks, followed by random assignment to either placebo or atrasentan 0.75 mg/day for responders (≥30% UACR decrease)
Number of subjects: 3500
Study 29405626 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan 0.75 mg/day for non-responders (<30% UACR reduction)
Number of subjects: 3500
Study 29405626 — intervention group
Group type: COMPARATOR
Intervention: Placebo for responders (≥30% UACR decrease)
Number of subjects: 3500
Study 29405626 — intervention group
Group type: COMPARATOR
Intervention: Placebo for non-responders (<30% UACR reduction)
Number of subjects: 3500
Study 29406178 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hscTnT) plasma concentrations measured at three time points: before operation, 2-6 h, and 18-30 h after surgery
Number of subjects: 95
Study 29406178 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hscTnT elevation >99th % upper reference limit (URL)
Number of subjects: 95
Study 29406378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric residents as first laryngoscopists in PICUs with a Pediatric Critical Care Medicine fellowship
Number of subjects: 9203
Study 29406378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric residents as first laryngoscopists in PICUs without a Pediatric Critical Care Medicine fellowship
Number of subjects: 9203
Study 29406378 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall resident participation trend
Number of subjects: 9203
Study 29406378 — intervention group
Group type: EXPERIMENTAL
Intervention: ICUs with a Pediatric Critical Care Medicine fellowship
Number of subjects: 9203
Study 29406378 — intervention group
Group type: EXPERIMENTAL
Intervention: ICUs without a Pediatric Critical Care Medicine fellowship
Number of subjects: 9203
Study 29406378 — intervention group
Group type: COMPARATOR
Intervention: Accreditation Council for Graduate Medical Education guideline change
Number of subjects: 9203
Study 29406443 — intervention group
Group type: EXPERIMENTAL
Intervention: EDC organs
Number of subjects: 79
Study 29406443 — intervention group
Group type: COMPARATOR
Intervention: Standard organs
Number of subjects: 79
Study 29406772 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol alone
Number of subjects: 16485
Study 29406772 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol combination
Number of subjects: 16485
Study 29406772 — intervention group
Group type: COMPARATOR
Intervention: Inhaled treatments (including vilanterol and fluticasone furoate/vilanterol)
Number of subjects: 16485
Study 29406851 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine Stress Echocardiography (DSE) with peak stress mean gradient (MG) ≥40 mm Hg
Number of subjects: 186
Study 29406851 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of peak stress MG ≥40 mm Hg and peak stress aortic valve area (AVA) ≤1 cm
Number of subjects: 186
Study 29406857 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine-18-NaF PET-CT
Number of subjects: 92
Study 29406857 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (aortic diameter <30 mm)
Number of subjects: 92
Study 29407077 — intervention group
Group type: EXPERIMENTAL
Intervention: BleeMACS risk score
Number of subjects: 15401
Study 29407124 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic detection of asymptomatic MSAD combined with aggressive secondary prevention (n=263)
Number of subjects: 521
Study 29407124 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy based on treatment of coronary artery disease only with standard of care (n=258)
Number of subjects: 521
Study 29407124 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic detection of asymptomatic MSAD combined with aggressive secondary prevention
Number of subjects: 521
Study 29407124 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy based on treatment of coronary artery disease only with standard of care
Number of subjects: 521
Study 29407285 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment during mania
Number of subjects: 19
Study 29407285 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment during euthymia
Number of subjects: 19
Study 29407681 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking to cope
Number of subjects: 341
Study 29408205 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation-positive families
Number of subjects: 1226
Study 29408205 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation-negative families
Number of subjects: 1226
Study 29408205 — intervention group
Group type: EXPERIMENTAL
Intervention: Both mutation-positive and mutation-negative families
Number of subjects: 1226
Study 29408205 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 1226
Study 29408538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastest tertile of quadriceps rate of force development (RFD)
Number of subjects: 2630
Study 29408538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastest tertile of quadriceps rate of force development (RFD) in women
Number of subjects: 2630
Study 29408538 — intervention group
Group type: COMPARATOR
Intervention: Slowest tertile of quadriceps rate of force development (RFD)
Number of subjects: 2630
Study 29408538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastest tertile of quadriceps rate of force development (RFD) in men
Number of subjects: 2630
Study 29408585 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Esophageal Sphincter Assist Device
Number of subjects: 0
Study 29408590 — intervention group
Group type: EXPERIMENTAL
Intervention: Large Portion Size (PS) High Energy Density (ED)
Number of subjects: 47
Study 29408590 — intervention group
Group type: COMPARATOR
Intervention: Small Portion Size (PS) High Energy Density (ED)
Number of subjects: 47
Study 29408590 — intervention group
Group type: EXPERIMENTAL
Intervention: Large Portion Size (PS)
Number of subjects: 47
Study 29408590 — intervention group
Group type: COMPARATOR
Intervention: Small Portion Size (PS)
Number of subjects: 47
Study 29408590 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses in food salience regions
Number of subjects: 47
Study 29408590 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation in control regions
Number of subjects: 47
Study 29408715 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut extract stimulation for 6 to 18 hours
Number of subjects: 0
Study 29408715 — intervention group
Group type: COMPARATOR
Intervention: Peanut allergy (PA)
Number of subjects: 0
Study 29408715 — intervention group
Group type: COMPARATOR
Intervention: Healthy control (HC) subjects
Number of subjects: 0
Study 29408981 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected individuals on a low-sodium controlled diet
Number of subjects: 30
Study 29408981 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected individuals
Number of subjects: 30
Study 29408981 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected individuals with BMI ≥25 kg/m2
Number of subjects: 30
Study 29408981 — intervention group
Group type: COMPARATOR
Intervention: Non-HIV-infected individuals with BMI <25 kg/m2
Number of subjects: 30
Study 29408981 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison across four groups stratified by HIV serostatus and BMI
Number of subjects: 30
Study 29408986 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 854
Study 29408986 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 every 3 weeks)
Number of subjects: 854
Study 29408986 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab in patients with liver metastases
Number of subjects: 854
Study 29408986 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel in patients with liver metastases
Number of subjects: 854
Study 29408986 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (overall population)
Number of subjects: 854
Study 29408986 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (liver metastases)
Number of subjects: 854
Study 29408986 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (overall population)
Number of subjects: 854
Study 29409025 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (Nordic diet recommendations and at least 150 minutes of moderate exercise weekly)
Number of subjects: 200
Study 29409025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 200
Study 29409462 — intervention group
Group type: EXPERIMENTAL
Intervention: FREGAT database (prospective database)
Number of subjects: 0
Study 29409462 — intervention group
Group type: COMPARATOR
Intervention: Standard treatments (endoscopy and surgery)
Number of subjects: 0
Study 29409462 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatments (including chemotherapy, targeted therapies, immunotherapy, radiotherapy, and surgery)
Number of subjects: 0
Study 29409871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (130 mg or approximately 6 mg/kg intravenous dose for 8 weeks; 90 mg subcutaneous injections every 8 or 12 weeks for 44 weeks)
Number of subjects: 0
Study 29409871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (subcutaneous injections every 8 or 12 weeks for 44 weeks)
Number of subjects: 0
Study 29409871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (various doses)
Number of subjects: 0
Study 29409871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 0
Study 29410163 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation in the ED or hospital for > 12 to < 24 h, followed by outpatient management with FDA-approved therapeutic anticoagulation.
Number of subjects: 200
Study 29410304 — intervention group
Group type: EXPERIMENTAL
Intervention: POEM
Number of subjects: 143
Study 29410330 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 2
Study 29410385 — intervention group
Group type: EXPERIMENTAL
Intervention: PENFS treatment group (10 subjects)
Number of subjects: 20